AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01621165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
Study NCT02164279 — intervention group
Intervention type: OTHER
Intervention: Urinary sample collection
Description: urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( \< or > than 100mg/L)
Study NCT00998023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mynx Vascular Closure Device
Description: Comparison of two different vascular closure devices.
Study NCT00998023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AngioSeal Vascular Closure Device
Description: Comparison of two different vascular closure devices.
Study NCT00213421 — intervention group
Intervention type: DRUG
Intervention: Dermoval
Description: group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight > 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth > 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
Study NCT01357278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation and patient education
Description: Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week.
Study NCT02066922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT02066922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT02066922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narafilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT02066922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT02066922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Incremental prescription worn over contact lenses if needed to provide acceptable vision
Study NCT02066922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Incremental prescription worn over contact lenses if needed to provide acceptable vision
Study NCT03619005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Insert
Description: Daily administration of a placebo vaginal insert.
Study NCT03619005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasterone 6.5 mg (0.50%) Vaginal Insert
Description: Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Study NCT01366508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High calorie lunch
Description: Subject fed a standard high calorie lunch at 1pm
Study NCT01366508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast
Description: At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.
Study NCT03280797 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: 2ml blood taken into TruCulture tube
Study NCT04370665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate BBBD with Cerezyme
Description: Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro
Study NCT03480425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measuring extubation force
Description: Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
Study NCT05647031 — intervention group
Intervention type: OTHER
Intervention: Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.
Description: This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data.
Study NCT03405402 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
Study NCT03405402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
Study NCT00938171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
Study NCT00938171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
Study NCT02157220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed bearing prosthesis
Study NCT02157220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile bearing prosthesis
Study NCT00814463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MMSE
Description: Neurocognitive function via MMSE done every 3 months for length of study.
Study NCT00814463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QOL via FACT-Br
Description: Quality of Life via FACT-BR every 3 months for length of study.
Study NCT00814463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI done every 3 months for the length of the study.
Study NCT00814463 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative SRS
Description: Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
Study NCT00731705 — intervention group
Intervention type: PROCEDURE
Intervention: collection of peripheral blood and apheresis samples
Description: Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
Study NCT00939003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg every other week up to Week 12
Study NCT00939003 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every other week up to Week 12
Study NCT00939003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label Adalimumab
Description: 40 mg every other week, Week 12 through Week 156
Study NCT00951925 — intervention group
Intervention type: OTHER
Intervention: Bone Marrow Aspirate Draw
Description: 5cc of Bone Marrow Aspirate will be drawn
Study NCT03884439 — intervention group
Intervention type: DRUG
Intervention: Infliximab [infliximab biosimilar 3]
Description: \<Crohn's disease> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. \<Ulcerative colitis> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
Study NCT03476460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sodium chloride
Description: Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
Study NCT03476460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sodium chloride
Description: Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
Study NCT02592161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks
Study NCT02592161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks
Study NCT02978586 — intervention group
Intervention type: DEVICE
Intervention: [Ga-68]PSMA PET/MR
Description: All participants will undergo at least 1 baseline \[Ga-68\]PSMA PET/MR. If participants test positive for \[Ga-68\]PSMA tumor uptake, they will under up to 2 additional scans
Study NCT00118547 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In home monitoring with feedback
Description: Behavioral counseling
Study NCT03300934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed loop glucose control system
Description: Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
Study NCT02745899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cow milk
Description: Ingestion of 240 ml cow milk
Study NCT02745899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy milk
Description: Ingestion of 240 ml soy milk
Study NCT04220151 — intervention group
Intervention type: GENETIC
Intervention: DNA methylation
Description: DNA methylation will be measured by real time polymerase chain reaction
Study NCT06772922 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: effect of exercise after three months (comparison of the patient with himself)
Study NCT01041911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphorbia tablets
Description: 50 mg, tablet, once daily, 14 days
Study NCT01041911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphorbia tablets
Description: 100 mg, tablet, once daily, 14 days
Study NCT01041911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphorbia tablets
Description: 200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
Study NCT01041911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: placebo, tablet, once daily, 14 days
Study NCT01346098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy with pancreatic anastomosis
Description: Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
Study NCT01346098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total pancreatectomy with islet autotransplantation
Description: If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
Study NCT03247309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA201 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
Study NCT03247309 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
Study NCT01853865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction in self-referral
Study NCT02499562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
Study NCT02499562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02499562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Study NCT05126693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.
Description: BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
Study NCT01124253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study NCT01124253 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study NCT02854462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language comprehension intervention
Study NCT02854462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counting intervention
Study NCT03188822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid releasing sinus implant
Description: After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
Study NCT03188822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable nasal dressing impregnated with steroid
Description: After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
Study NCT01260129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Silodosin 8 mg orally, once daily after morning meal
Study NCT01260129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Silodosin 4 mg orally, twice daily after morning and evening meal
Study NCT00643175 — intervention group
Intervention type: BEHAVIORAL
Intervention: Automated follow up
Description: Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
Study NCT03042689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
Study NCT04290104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1gr oral ampicillin/sulbactam group
Description: Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.
Study NCT02320175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient and Family Centered I-PASS
Description: Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
Study NCT02910232 — intervention group
Intervention type: DEVICE
Intervention: bone void filler
Description: Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
Study NCT03136198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LUS-guided strategy-of-care
Description: For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~3. Reassessment every 2 hours
Study NCT03136198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patients will receive usual AHF care
Study NCT03136198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Loop Diuretic
Description: IV loop diuretic
Study NCT03136198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Loop Diuretic
Description: IV loop diuretic